Drug Profile
Research programme: protein-based hemojuvelin inhibitors - Xenon Pharmaceuticals
Alternative Names: HJV inhibitors - Roche/XenonLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Class Proteins
- Mechanism of Action HFE2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Anaemia in Canada (Parenteral)
- 02 Jun 2010 Early research is ongoing in Canada
- 08 Dec 2006 Early research in Anaemia in Canada (unspecified route)